Lilly/Incyte's baricitinib still has more to do in RA
This article was originally published in Scrip
The full data for Lilly/Incyte's Phase III RA-BUILD and RA-BEACON studies of their novel oral JAK 1 and 2 inhibitor baricitinib presented at EULAR in Rome this week confirm its promising efficacy but some experts want to see still more safety data.
You may also be interested in...
Lilly priced its now-approved Olumiant (baricitinib) to fight for US market share versus well-known rheumatoid arthritis therapies, undercutting Humira by 60% and Pfizer's established JAK inhibitor Xeljanz by 50%.
2021 saw a record number of novel drug launches and the size of the pipeline topped 20,000 candidates for the first time, new analysis shows, while China came of age as a pharma player.
Ahead of the American Society of Clinical Oncology meeting in early June, analysts at Biomedtracker have highlighted select high-impact late-breaking abstracts that are due to presented, including therapies from AbbVie, Gilead Sciences, Pfizer, Takeda, Amgen, AstraZeneca and Daiichi Sankyo.